Natural Berry Extract Treatment of Hemangiomas (Pediaberry)
Sponsor: Gayle Gordillo
Terminated
Study ending early due to program transferring to another site.
Other terminated trials from Gayle Gordillo
More terminations from Gayle Gordillo
Listed as NCT04020419, this EARLY_PHASE1 trial focuses on Hemangioma and remains terminated or withdrawn. Sponsored by Gayle Gordillo, it has been updated 12 times since 2020, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Terminated EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated EARLY_PHASE1
-
Nov 2023 — Jul 2024 [monthly]
Terminated EARLY_PHASE1
Status: Recruiting → Terminated
-
Jun 2023 — Nov 2023 [monthly]
Recruiting EARLY_PHASE1
-
Sep 2022 — Jun 2023 [monthly]
Recruiting EARLY_PHASE1
▶ Show 7 earlier versions
-
Sep 2021 — Sep 2022 [monthly]
Recruiting EARLY_PHASE1
-
Mar 2021 — Sep 2021 [monthly]
Recruiting EARLY_PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Mar 2021 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
May 2020 — Jan 2021 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
Oct 2019 — May 2020 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
Sep 2019 — Oct 2019 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
Aug 2019 — Sep 2019 [monthly]
Not Yet Recruiting EARLY_PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Gayle Gordillo
- National Institute of General Medical Sciences (NIGMS)
- National Institutes of Health (NIH)
For direct contact, visit the study record on ClinicalTrials.gov .